Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Towards a commercial process for the manufacture of genetically modified T cells for therapy

23 Jan 2015

Abstract excerpt

The recent successes of adoptive T-cell immunotherapy for the treatment of hematologic malignancies have highlighted the need for manufacturing processes that are robust and scalable for product commercialization. Here we review some of the more outstanding issues surrounding commercial scale manufacturing of personalized-adoptive T-cell medicinal products. These include closed system operations, improving...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biomedical Ethics and Regulation
Share to CAR-T cell therapy research

Source

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Identifiers

PMID: 25613483
DOI: 10.1038/cgt.2014.78

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Towards a commercial process for the manufacture of genetically modified T cells for therapyPMID 25613483Read ↗

Towards automated manufacturing of clinical scale gene-modified T cellsSemantic proximity Read ↗

Development of an optimized closed and semi-automatic protocol for Good Manufacturing Practice manufacturing of tumor-infiltrating lymphocytes in a hospital environment.Semantic proximity Read ↗

Revolutionizing CAR T Cell Therapies: Innovations in Genetic Engineering and Manufacturing to Enhance Efficacy and AccessibilitySemantic proximity Read ↗

Toward precision manufacturing of immunogene T-cell therapiesSemantic proximity Read ↗

Manufacturing Cell and Gene Therapies: Challenges in Clinical TranslationSemantic proximity Read ↗

GMP manufacturing of cell and gene therapy products: Challenges, opportunities, and pathways forwardSemantic proximity Read ↗

Fully Integrated downstream process to enable Next Generation ManufacturingSemantic proximity Read ↗

Definition and application of good manufacturing process-compliant production of CEA-specific chimeric antigen receptor expressing T-cells for phase I/II clinical trialSemantic proximity Read ↗

A closed, autologous bioprocess optimized for TCR-T cell therapiesSemantic proximity Read ↗

Scaling up and scaling out: Advances and challenges in manufacturing engineered T cell therapiesSemantic proximity Read ↗

Manufacturing genetically modified T cells for clinical trialsSemantic proximity Read ↗

High-density microbioreactor process designed for automated point-of-care manufacturing of CAR T cellsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.